C4 Therapeutics (CCCC) Total Non-Current Liabilities (2020)

C4 Therapeutics' (CCCC) quarterly Total Non-Current Liabilities came in at $123.1 million in Q3 2020.

C4 Therapeutics (CCCC) Total Non-Current Liabilities (2020) Analysis & Trends

C4 Therapeutics' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $123.1 million for Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	4.45 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.28 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.98 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	949,738.67
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.87 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	7.32 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	40.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	746.94 Mn
10	C4 Therapeutics	460.17 Mn	224.50 Mn	-	-

Download Data

Date	Value
Sep 30, 2020	123.07 Mn